Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6106861 | JAZZ | Multiparticulate tablet disintegrating in less than 40 seconds in the mouth |
Dec, 2017
(6 years ago) | |
US6024981 | JAZZ | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
US6221392 | JAZZ | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) |
Drugs and Companies using CLOZAPINE ingredient
Market Authorisation Date: 30 May, 2007
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8731963 | JAZZ | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
US8731963 (Pediatric) | JAZZ | Sensitive drug distribution system and method |
Jun, 2023
(10 months ago) | |
US11554102 | JAZZ | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
Jan, 2033
(8 years from now) | |
US10675258 | JAZZ | Method of using gamma-hydroxybutyrate compositions for the treatment of disorders |
Jan, 2033
(8 years from now) | |
US9132107 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(8 years from now) | |
US8901173 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(8 years from now) | |
US10195168 | JAZZ | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
Jan, 2033
(8 years from now) | |
US8591922 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(8 years from now) | |
US10864181 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
US11253494 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
US9050302 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
US10213400 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
US9486426 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
US8772306 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
US10864181 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
US8772306 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
US11253494 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
US9050302 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
US10213400 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
US9486426 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
US11426373 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Sep, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-361) | Jul 21, 2027 |
New Indication(I-870) | Aug 12, 2024 |
Orphan Drug Exclusivity(ODE-369) | Aug 12, 2028 |
Orphan Drug Exclusivity(ODE-231) | Jul 21, 2027 |
New Product(NP) | Jul 21, 2023 |
Market Authorisation Date: 21 July, 2020
Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years ...
Dosage: SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7763615 | JAZZ | Ecteinascidin analogs for use as antitumour agents |
Dec, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 15, 2025 |
Orphan Drug Exclusivity(ODE-304) | Jun 15, 2027 |
Drugs and Companies using LURBINECTEDIN ingredient
NCE-1 date: 15 June, 2024
Market Authorisation Date: 15 June, 2020
Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.
Dosage: POWDER;INTRAVENOUS